Of 90 patients, 49 were classified as MND (57%), 17 as MN (19.8%), 20 as non-diagnostic (23.2%), and 4 as technically non-evaluable (4.4%). At follow-up, the pathological diagnosis showed a sensitivity and specificity of 78% and 88.9% for ALS, and 85% and 100% for MN, respectively.
The outcomes were also used to retrospectively validate the new-revised El Escorial Criteria (NR-EEC) in ALS and ALS-mimics. Compared to the older version of these criteria, NR-EEC showed a significant increase in sensitivity: 45.9% versus 11%. The degree of axonal degeneration was associated with shortened survival in ALS. TAR DNA-binding protein-43 (TDP-43)-immunoreactivity in motor nerves correlated with the risk of developing ALS and could be a potential new biomarker for ALS.
- Riva N, et al. EAN 2019, O4121.
Posted on
Previous Article
« Promising results of novel NMOSD treatments Next Article
Epigallocatechin gallate does not modify MSA progression »
« Promising results of novel NMOSD treatments Next Article
Epigallocatechin gallate does not modify MSA progression »
Table of Contents: EAN 2019
Featured articles
Letter from the Editor
Alzheimer’s Disease and other Dementias
A necessary shift of focus to the earlier stages of Alzheimer’s
Antipsychotics increase mortality regardless of comorbidity
Epilepsy
Neuroinflammatory pathways as biomarkers and treatment targets
Long-term effect of recurrent febrile seizures
Migraine
The role of neurogenic inflammation in migraine
Multiple Sclerosis
Treating MS from disease onset
Randomised and observational studies comparing treatments
Autologous haematopoietic stem cell transplantation
Neuromuscular Disorders
Parkinson's Disease and other Movement Disorders
Inflammation may change the course of Parkinson’s disease
Opicapone: follow-up on the BIPARK I and II trials
Epigallocatechin gallate does not modify MSA progression
Stroke
Thrombo-inflammation during ischaemia/reperfusion
Related Articles
January 11, 2022
Drug-eluting stents reduce in-stent restenosis, stroke
© 2024 Medicom Medical Publishers. All rights reserved. Terms and Conditions | Privacy Policy